All In MedTech

Device Trial Radar · NCT06405984

Trans-Abdominal Fetal Pulse Oximetry - EFS-IDE

Trans-Abdominal Fetal Pulse Oximetry - An Early Feasibility Study

Last checked: Nov 20, 2026Latest source record: Oct 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

35

Actual

Start

Apr 15, 2024

Primary completion

Oct 17, 2025

Study completion Oct 17, 2025

Sponsor

Lead sponsor
Raydiant Oximetry, Inc.Not on our public-company list
Sponsor type
Industry
Collaborators
National Institutes of Health (NIH); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
First posted
May 9, 2024

More device trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Device feasibility
FDA-regulated device
Yes
Who can join
Female only, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The Lumerah System, developed and manufactured by Raydiant Oximetry, Inc., is a non-invasive fetal pulse oximeter that measures fetal arterial oxygen saturation using safe, non-invasive, transabdominal near-infrared spectroscopy. The Lumerah System is intended as an adjunct to cardiotocography. In this study, women in labor will also be simultaneously monitored with a re-engineered version of the previously approved transvaginal oximeter sensor connected to a Nellcor N-400 fetal oximetry monitor for the purposes of device development. The data obtained from the transabdominal sensor and the transvaginal sensor will be used for research purposes only and will not be used to guide or alter patient management.

Conditions

  • Fetal Hypoxia
  • Fetal Distress
  • Fetal Conditions
  • Fetal Complications
  • Labor Fetal Anoxia
  • Labor (Obstetrics)--Complications
  • Oxygen Deficiency

Interventions

  • Fetal Oxygenation MeasurementsDevice

    The Lumerah device, and Oxiplex ISS will be positioned on the maternal abdomen in various locations depending on the sonographic evaluation. The transvaginal sensor will be placed after rupture of the maternal membranes and appropriate descent of the fetus.This study is for data collection purposes only. Neonates of this study arm will also be monitored with the Oxiplex ISS system. This study is for data collection purposes only.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Feasibility of monitoring fetal signals.Time frame: During labor for up to 6 hours

1 more outcomes with a free account

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sentara Norfolk General - Eastern Virginia Medical School

    Norfolk, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.